Home › Clinical Trials › Oncology
01 · Therapeutic Area

Oncology Clinical Trials

Phase 2 and 3 cancer trials, dominated by time-to-event endpoints: overall and progression-free survival, hazard ratios, stratified log-rank tests, and response rates.

1,418 trials in this area

Statistical methods in oncology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

Hazard ratio Used in 33% of oncology trials · Hazard Ratio Interpretation for Clinicians → Log-rank test Used in 27% of oncology trials · Log-Rank Test for Comparing Survival Curves → Cochran-Mantel-Haenszel test Used in 10% of oncology trials · SAS PROC FREQ for Categorical Data Analysis → Odds ratio Used in 9% of oncology trials · Effect Size Measures in Clinical Research → Cox proportional-hazards model Used in 7% of oncology trials · Cox Proportional Hazards: Model Diagnostics → Fisher exact test Used in 4% of oncology trials · Fisher's Exact Test for Small Sample Sizes → Risk difference Used in 4% of oncology trials · Effect Size Measures in Clinical Research → Stratified log-rank test Used in 4% of oncology trials · Log-Rank Test for Comparing Survival Curves →

All oncology trials

1,418 results

← All therapeutic areas

Clinical Biostats